Business Wire

VALBIOTIS

21.9.2020 07:37:09 CEST | Business Wire | Press release

Share
VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)

Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the selection of 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD), which will be presented at the association's annual meeting in September 2020.

For the third consecutive year, VALBIOTIS has seen its results on TOTUM-63, its active substance designed to reduce the risk of type 2 diabetes, selected by the main European diabetes meeting. This year, VALBIOTIS will present 3 studies at this major event, to be held from 22 to 25 September in virtual format due to the COVID-19 pandemic.

The clinical results of the international Phase II study of TOTUM-63 will first be presented by Prof. Jean-Marie Bard in the form of an e-poster (Abstract #621). Completed in the summer of 2019, this study showed a significant reduction in the main risk factors for type 2 diabetes (glycemic parameters, waist circumference, body weight) in prediabetic people, compared to a placebo. Already selected by the American Diabetes Association last June, these results have now been accepted by the two main scientific societies in the field of diabetes worldwide.

Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The excellent results of the TOTUM-63 Phase II clinical study exceeded our expectations and enabled us to enter into a strategic partnership with Nestlé Health Science last February. In 2020, we have launched a strategy for the scientific communication of these results, which has already led to selection for presentations at the two largest diabetes meetings in the world, the ADA and EASD, within three months. These publications constitute indisputable recognition of the quality of our work. They are also a great source of pride and an additional incentive to complete the clinical development of TOTUM-63 with our partner Nestlé Health Science."

In addition to these clinical results, two preclinical studies demonstrating the positive effects of TOTUM-63 on obesity and carbohydrate metabolism disorders have also been selected by the EASD (Abstract #448 and #623). These studies highlight the efficacy of TOTUM-63 through two protocols: a protocol for the prevention of weight gain and associated metabolic disorders, carried out by the VALBIOTIS teams, and a protocol for the management of obesity and acquired disorders, carried out by the team of Dr Bruno Guigas (University of Leiden, Netherlands) with Vanderbilt University (Nashville, USA), one of the American expert centers for the study of diabetes. This preclinical work shows a reduction in body weight thanks to TOTUM-63 as well as an improvement in carbohydrate parameters in both protocols. It also provides a better understanding of the multi-targeted mode of action of TOTUM-63: reduced intestinal absorption of lipids and glucose, increased sensitivity of peripheral tissues to insulin and increased energy expenditure.

Pascal SIRVENT, member of the Management Board, Director of Discovery, Preclinical and Translational Research, states: "Since 2014, we have been conducting extensive preclinical work on TOTUM-63 in partnership with French and international universities, such as Leiden (the Netherlands) or Vanderbilt (USA) universities. These additional studies are essential, as they guide the clinical development of the active substances and document their mode of action. The two studies selected have demonstrated promising additional effects on the prevention and reversal of weight gain and its consequences on carbohydrate metabolism. We are now very proud to present them to the European diabetology community."

The three VALBIOTIS presentations at the EASD 2020 meeting are available at www.valbiotis.com/scientific-publications .

ABOUT TOTUM-63
TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the physiopathological mechanisms of type 2 diabetes.
TOTUM-63 has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study. Results of an international randomized, placebo-controlled Phase II study showed that TOTUM-63 reduced fasting and 2-hour blood glucose levels, two risk factors for type 2 diabetes, compared to placebo. In these subjects, who also had abdominal obesity, TOTUM-63 also significantly reduced body weight and waist circumference.
TOTUM-63 benefits from intellectual property that has been validated by the granting of patents in the main world markets: Europe (covering 39 countries), the United States and Russia, and national phases are underway in more than 20 countries including China, Japan, Brazil and Australia. TOTUM-63's industrial production capacity, in accordance with North American and European standards, has been validated. TOTUM-63 already has marketing authorizations linked to its status in Europe.
In February 2020, VALBIOTIS signed a long-term global strategic partnership with Nestlé Health Science for the development and worldwide marketing of TOTUM-63. This unique partnership in the field of Health Nutrition provides for the worldwide marketing of TOTUM-63 by Nestlé Health Science, possibly before obtaining a health claim depending on the region. It will also finance the final stages of development of TOTUM-63.

ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL

DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120--018). This document is available on the Company’s website (www.valbiotis.com ).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release

Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release

Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release

Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release

The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release

Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye